Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment
Zhou, X., Cella, D., Cameron, D., Amonkar, MM., Segreti, A., Stein, S., Walker, M., & Geyer, CE. (2009). Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment, 117(3), 577-589.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.